Wire · opportunities
Amgen deploys patients to defend troubled Tavneos in FDA hearing request
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 July 2026 · Fusion42 review
Amgen is requesting an FDA hearing to defend Tavneos against a withdrawal recommendation, citing real-world evidence of benefit despite liver toxicity concerns that triggered safety alerts in the US, Japan, and Europe. The rare kidney disease drug faces mounting regulatory pressure globally after deaths and liver injuries emerged post-approval.
This Wire brief sits within Fusion42's coverage of Digital Health, and 2 sources have reported it between 24 Jul 2026 and 25 Jul 2026.
◆ ◆ The Wire takeaway
If you're building safety surveillance tools or post-market data platforms for rare disease, this is your market moment. Amgen just proved that real-world evidence is the last card in the FDA's hand - whoever collects and frames that data first will own the next drug defence.
◆ Coverage
2 sources · first reported 24 Jul 2026 · latest 25 Jul 2026
◆ Related on Wire
◆ Topics